NCT02283749View on ClinicalTrials.gov

BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

July 5, 2018

Study Completion Date

November 13, 2018

Conditions
Non Small Cell Lung Cancer With Bone Metastatses
Interventions
BIOLOGICAL

Xofigo

This is a radio-isotope

Trial Locations (1)

02903

Rhode Island Hospital and The Miriam Hospital, Providence

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Rhode Island Hospital

OTHER

collaborator

The Miriam Hospital

OTHER

collaborator

Bayer

INDUSTRY

lead

Angela Taber MD

OTHER